Testing Novel Pharmacogenetic and Adherence Optimization Treatments to

Recruiting

18 years - 99 years

All

Phase 3

244 participants needed

1 Location

Brief description of study

The research study is being conducted to examine the effects of personalized smoking cessation medication treatment in order to help people with HIV/AIDS to quit smoking. During the study, participants will take either varenicline (brand name Chantix®) or use the nicotine patch, and they will receive smoking cessation therapy with either standard smoking cessation medication adherence advice or Managed Problem Solving intervention (MAPS).

If you agree to join the study, you will be asked to complete the following research procedures:

· Attend 3 in person sessions (including this one) and complete 5 phone sessions.

· Take the study medication (either varenicline or nicotine patch) for up to 12 weeks.

· Complete up to 5 smoking cessation therapy sessions.

· Provide biological samples and physiological assessments.

· Complete brief psychiatric assessments and a routine medical history.

Your individual participation will last for about 7 months. By participating in this research study, you will have the opportunity to participate in a smoking cessation program, which includes counseling and varenicline and/or nicotine patch, at no cost.

If you are interested please click the following link to see if you are eligible:

PENN HTO Recruitment Survey

Detailed description of study

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Smoking,HIV
Age: 18 years - 99 years
Gender: All

Updated on 19 Feb 2024. Study ID: 834345

Pre-Screener

Compruebe si es elegible Ingrese los datos de contacto Selecciona un centro de estudios Select best time to contact

Are you a current smoker?

Yes or No

Preview complete

The prescreener preview is complete. You may now close the preview.